A recent report has described multi-specific anti-mutated IDH1/2 mAbs, MsMab-1 [22] and MsMab-2 [23], which are useful for diagnosis of IDH1/2 mutation-bearing gliomas. This evidence concerns the gene IDH1 and glioma.